rosiglitazone has been researched along with Movement Disorders in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Albertz, J; Duan, W; Guo, Z; Jin, J; Peng, Q; Ross, CA; Rudow, G; Troncoso, JC | 1 |
1 other study(ies) available for rosiglitazone and Movement Disorders
| Article | Year |
|---|---|
Neuroprotective effects of PPAR-γ agonist rosiglitazone in N171-82Q mouse model of Huntington's disease.
Topics: Adenosine Triphosphate; Anilides; Animals; Brain; Brain-Derived Neurotrophic Factor; Cell Line; Disease Models, Animal; Gene Expression Regulation; Glutamates; Humans; Huntingtin Protein; Huntington Disease; Hyperglycemia; Intracellular Signaling Peptides and Proteins; L-Lactate Dehydrogenase; Male; Mice; Mice, Transgenic; Movement Disorders; Nerve Tissue Proteins; Neurons; Neuropeptides; Neuroprotective Agents; Orexins; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; PPAR gamma; RNA, Messenger; Rosiglitazone; Sirtuins; Thiazolidinediones; Trans-Activators; Transcription Factors; Transfection; Trinucleotide Repeat Expansion | 2013 |